CIBC World Markets’s Praxis Precision Medicines PRAX Stock Holding History

CIBC World Markets’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$439K	Buy	+1,490	New	+$277K	﹤0.01%	860

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CIBC World Markets's PRAX Position: Q4 2025 in Review

CIBC World Markets opened a new position in Praxis Precision Medicines (PRAX) in Q4 2025: 1,490 shares worth $439K. The stake represents ﹤0.01% of the portfolio and ranks #860 among its holdings.

250 funds tracked by Wall St. Rank hold PRAX as of Q4 2025.

CIBC World Markets held 1,490 shares of Praxis Precision Medicines worth $439K as of Q4 2025.
Praxis Precision Medicines was a new CIBC World Markets position in Q4 2025.
Praxis Precision Medicines made up ﹤0.01% of CIBC World Markets's portfolio in Q4 2025, its #860 holding.
250 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2025.

Based on CIBC World Markets's 13F filing for Q4 2025, filed 12 Feb 2026.